RenovoRx, Inc. (Nasdaq: RNXT), a clinical-stage biopharmaceutical company dedicated to advancing precision oncology therapies through its local drug-delivery platform, announced today the significant promotions of Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak, CPA to Principal Accounting Officer.
Shaun Bagai, CEO of RenovoRx, expressed his enthusiasm regarding these promotions, stating, “We are thrilled to elevate Leesa and Ron to their new leadership positions, underscoring our commitment to building a dynamic team positioned to drive the success of our proprietary therapy platform. We have streamlined our team’s focus on strategic initiatives aimed at fostering growth and innovation. On behalf of our Board of Directors, I extend our appreciation to Leesa and Ron for their hard work and dedication thus far, and I congratulate them on their well-deserved promotions.”
Ms. Gentry has been serving as Senior Vice President of Clinical Operations at RenovoRx since April 2023. In her new role as Chief Clinical Officer, she will be responsible for overseeing clinical and regulatory operations to ensure the highest standards of safety and quality across RenovoRx’s clinical studies. Ms. Gentry will continue to leverage her extensive experience as the Company advances toward a second interim analysis for the Phase III TIGeR-PaC study evaluating RenovoRx’s lead product candidate, RenovoGem™, for the treatment of Locally Advanced Pancreatic Cancer (LAPC), expected by late 2024.
Since joining RenovoRx, Ms. Gentry has demonstrated exceptional leadership and dedication to advancing the Company’s clinical pipeline. In 2023, she played a key role in achieving the first interim analysis in the TIGeR-PaC study, with the Data Monitoring Committee recommending the continuation of the study. The primary endpoint of the TIGeR-PaC study is a 6-month Overall Survival benefit, with secondary endpoints including reduced side effects compared to standard of care. Under her guidance, the Company’s clinical strategy has yielded positive results, aligning with its mission to enhance patients’ lives and lifespans by delivering transformative cancer care therapies.
Mr. Kocak has been promoted to the position of Principal Accounting Officer while retaining his roles as Vice President and Controller of RenovoRx. He joined the Company in October 2021, bringing with him extensive financial reporting and accounting expertise in the life sciences industry. Mr. Kocak played a pivotal role in the recent completion of a $6.1 million private placement, extending RenovoRx’s cash runway to support its clinical program initiatives. In his new leadership role, Mr. Kocak will oversee all financial management, reporting, and strategic planning initiatives critical to advancing the Company’s research and development efforts.
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company focused on developing proprietary targeted combination therapies to address high unmet medical needs and improve therapeutic outcomes for cancer patients. The Company’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to deliver precise therapeutic agents directly to the tumor, potentially minimizing treatment-related toxicities compared to systemic therapy. RenovoRx’s unique targeted treatment approach offers the potential for increased safety, tolerance, and efficacy. Its Phase III lead product candidate, RenovoGem™, a novel oncology drug-device combination product, is currently being investigated for the treatment of locally advanced pancreatic cancer (LAPC) under a US IND regulated by the FDA. RenovoGem utilizes the TAMP therapeutic delivery of gemcitabine and is currently under investigation, with no commercial sale approval yet.
RenovoRx is dedicated to transforming cancer care by delivering innovative solutions to improve patient outcomes and change the current cancer treatment paradigm.
